This study supports further investigation of EMP2 as a therapeutic target for retinal neovascularization in diseases such as age-related macular degeneration (AMD), retinopathy of prematurity, and diabetic retinopathy. This evidence concerns the gene EMP2 and diabetic retinopathy.